Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. inflammatory action
Show results for
Products
Applications

Companies

News
Articles

Refine by
Date

  • Older

Inflammatory Action Articles & Analysis

4 news found

Dual Benefits of Compound 17B For Pulmonary Arterial Hypertension

Dual Benefits of Compound 17B For Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition characterized by increased pulmonary arterial pressure, vascular remodeling, and persistent inflammation. Despite advances in treatment, current therapies—such as sildenafil, iloprost, and riociguat—primarily focus on reducing symptoms by dilating blood vessels. Unfortunately, these therapies do ...

BySCIREQ - an emka TECHNOLOGIES Company


Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company’s Over-The-Counter Cosmeceutical Assets

Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company’s Over-The-Counter Cosmeceutical Assets

” LEA™, the Company’s novel small molecule has been shown in preclinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin cells irradiated with UVB-radiation were used in testing to monitor the comparison of the two substances. ...

ByNeuropathix, Inc.


Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders

Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders

LEA™, the Company’s novel small molecule has been shown in preclinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin cells irradiated with UVB-radiation were used in testing to monitor the comparison of the two substances. ...

ByNeuropathix, Inc.


Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine

Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine

In pre-clinical testing, Atopidine™ was shown to decrease inflammatory cytokine (TNFα, Il-1β, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. Atopidine™ was effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured ...

ByNeuropathix, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT